These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30499343)

  • 1. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection.
    Mensa FJ; Lovell S; Pilot-Matias T; Liu W
    Future Microbiol; 2019 Jan; 14():89-110. PubMed ID: 30499343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
    Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
    J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
    Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ
    Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
    Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
    Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older.
    Huff J; Andersen R
    Ann Pharmacother; 2020 Mar; 54(3):262-276. PubMed ID: 31537106
    [No Abstract]   [Full Text] [Related]  

  • 7. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
    Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
    Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
    Sho T; Suda G; Kimura M; Shimazaki T; Maehara O; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Izumi T; Kawagishi N; Baba M; Nakai M; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    Intern Med; 2019 Mar; 58(6):797-802. PubMed ID: 30449808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glecaprevir/Pibrentasvir: First Global Approval.
    Lamb YN
    Drugs; 2017 Oct; 77(16):1797-1804. PubMed ID: 28929412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
    Forns X; Lee SS; Valdes J; Lens S; Ghalib R; Aguilar H; Felizarta F; Hassanein T; Hinrichsen H; Rincon D; Morillas R; Zeuzem S; Horsmans Y; Nelson DR; Yu Y; Krishnan P; Lin CW; Kort JJ; Mensa FJ
    Lancet Infect Dis; 2017 Oct; 17(10):1062-1068. PubMed ID: 28818546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
    Cotter TG; Jensen DM
    Drug Des Devel Ther; 2019; 13():2565-2577. PubMed ID: 31534310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.
    Abutaleb A; Kottilil S; Wilson E
    Hepatol Int; 2018 May; 12(3):214-222. PubMed ID: 29845496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.
    Osawa M; Imamura M; Teraoka Y; Uchida T; Morio K; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Chayama K;
    J Gastroenterol; 2019 Mar; 54(3):291-296. PubMed ID: 30334096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.
    Rockstroh JK; Lacombe K; Viani RM; Orkin C; Wyles D; Luetkemeyer AF; Soto-Malave R; Flisiak R; Bhagani S; Sherman KE; Shimonova T; Ruane P; Sasadeusz J; Slim J; Zhang Z; Samanta S; Ng TI; Gulati A; Kosloski MP; Shulman NS; Trinh R; Sulkowski M
    Clin Infect Dis; 2018 Sep; 67(7):1010-1017. PubMed ID: 29566246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glecaprevir + pibrentasvir for treatment of hepatitis C.
    Carrion AF; Martin P
    Expert Opin Pharmacother; 2018 Mar; 19(4):413-419. PubMed ID: 29465262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
    Suda G; Nakai M; Sho T; Kimura M; Shimazaki T; Maehara O; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Baba M; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    Intern Med; 2019 Apr; 58(7):943-947. PubMed ID: 30568153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
    Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
    Kosloski MP; Zhao W; Asatryan A; Kort J; Geoffroy P; Liu W
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28807904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
    Gane E; Lawitz E; Pugatch D; Papatheodoridis G; Bräu N; Brown A; Pol S; Leroy V; Persico M; Moreno C; Colombo M; Yoshida EM; Nelson DR; Collins C; Lei Y; Kosloski M; Mensa FJ
    N Engl J Med; 2017 Oct; 377(15):1448-1455. PubMed ID: 29020583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.